Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma

Clin Lung Cancer. 2021 May;22(3):e481-e486. doi: 10.1016/j.cllc.2020.06.021. Epub 2020 Jul 2.

Authors

Luiza Lara Gadotti¹, Felipe Sales Nogueira Amorim Canedo², Maurício Fernando Silva Almeida Ribeiro², Karina Perez Sacardo², Rodrigo Saddi², João Victor Machado Alessi², Leonardo de Abreu Testagrossa³, Artur Katz²

Affiliations

¹ Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil. Electronic address: [email protected].
² Oncology Center, Hospital Sírio-Libanês, São Paulo, SP, Brazil.
³ Department of Anatomic Pathology and Molecular Pathology, Hospital Sírio-Libanês, São Paulo, SP, Brazil.

PMID: 32771343
DOI: 10.1016/j.cllc.2020.06.021

No abstract available

Keywords: ALK; Alectinib; Anaplastic lymphoma kinase inhibitor; Interstitial lung disease; Lung cancer.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Anaplastic Lymphoma Kinase / genetics
Carbazoles / administration & dosage*
Carbazoles / adverse effects
Gene Rearrangement
Humans
Lung Diseases, Interstitial / chemically induced*
Lung Diseases, Interstitial / physiopathology
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Male
Middle Aged
Patient Acuity
Piperidines / administration & dosage*
Piperidines / adverse effects

Substances

Carbazoles
Piperidines
ALK protein, human
Anaplastic Lymphoma Kinase
alectinib